United States: Washington Healthcare Update - February 17, 2014

Last Updated: February 21 2014
Article by Stephanie A. Kennan and Brian J. Looser

1. Congress


Energy and Commerce Hearing Examines Drug Shortage Issues

On Feb. 10, the Energy and Commerce Subcommittee on Health held a hearing entitled "Examining Drug Shortages and Recent Efforts to Address Them," in which members of the committee heard expert testimony from the Government Accountability Office (GAO) and the Food and Drug Administration (FDA) regarding the ongoing threat of drug shortages and what steps have been taken by FDA to address this issue, particularly after the enactment of the bipartisan Food and Drug Administration Safety and Innovation Act (FDASIA). FDASIA provided FDA with additional authorities to regulate drug manufacturing, and placed on drug manufacturers new requirements intended to help prevent and mitigate drug shortages. FDASIA also required GAO to compile a report on drug shortages and the role of FDA in resolving them.


Marcia Crosse, Ph.D.
Director, Health Care
U.S. Government Accountability Office

Douglas Throckmorton, M.D.
Deputy Director of Regulatory Programs
U.S. Food and Drug Administration

For more information, or to view the hearing, please visit energycommerce.house.gov.

Congress Approves SGR "Transitional Fund"

Last week, both the House and Senate approved legislation that would, in addition to insulating certain members of the military from a reduced annual cost-of-living adjustment as required by the Bipartisan Budget Act of 2013, create a $2.3 billion "transitional fund for sustainable growth rate reform." Under the legislation, the Secretary of HHS is to establish such a transition fund "to provide funds to pay for physicians' services under part B to supplement the conversion factor under section 1848(d) for 2017 if the conversion factor for 2017 is less than conversion factor for 2013." The bill passed the House by a vote of 326-90 on Feb. 11, and it passed the Senate the following day by a vote of 95-3.


Budget Committee Examines CBO Economic Outlook: 2014 to 2024

On Feb. 11, the Senate Budget Committee held a hearing entitled "CBO Budget and Economic Outlook," in which members of the committee heard testimony from Congressional Budget Office (CBO) Director Doug Elmendorf regarding CBO's report "The Budget and Economic Outlook: 2014 to 2024." The report represents CBO's baseline projections of what federal spending, revenues and deficits would look like over the next 10 years if current laws governing federal taxes and spending generally remained unchanged.

Dr. Douglas W. Elmendorf
Congressional Budget Office (CBO)

For more information, or to view the hearing, please visit: www.budget.senate.gov.

2. Administration

IRS Adds Delays to Employer Mandate Requirements

On Feb. 10, the IRS further amended its current delay of penalties associated with a failure of certain employers to provide qualified health coverage to its employees. Currently, any employer with 50 or more full-time employees or full-time equivalents (FTEs) must provide comprehensive health care coverage to full-time workers, or pay a tax penalty if any workers enroll in tax-subsidized health care coverage on the Health Insurance Exchanges (HIEs) established under the ACA. However, under the newly released rule, businesses with 50 to 99 employees would be exempted from these requirements for an additional year, until 2016. In addition, for 2015, employers with more than 100 employees will be required to offer qualifying coverage to at least 70 percent of its full-time employees in order to avoid paying a penalty. Such employers will not be required to offer coverage to 95 percent of its employees, as was previously required, until 2016.

3.3 Million Now Enrolled in Health Insurance Via ACA

On Feb. 12, HHS released updated ACA enrollment figures, finding that more than 1.1 million people signed up for coverage through state and federal health exchanges in January, which represents over one-third of the nearly 3.3 million people who have selected a plan through the ACA's health insurance exchanges. According to HHS, about 25 percent of people signing up for coverage through January were between the ages of 18 and 34 in the 36 states served by the federal marketplace -- up from 24 percent in last month's enrollment report. However, officials noted that the rate of signups among young people grew by 65 percent in January, compared to 55 percent for all other age groups combined.

Office of Medicare Hearings and Appeals (OMHA) Appellant Forum

On Feb. 12, the HHS Office of Medicare Hearings and Appeals held a Medicare Appellant Forum to provide updates to OMHA appellants on the status of OMHA operations, relay information on a number of OMHA initiatives designed to mitigate a growing backlog in the processing of Medicare appeals at the OMHA-level of the administrative appeals process, and provide information on measures that appellants can take to make the administrative appeals process work more efficiently at the OMHA-level. Of particular note, OMHA staff discussed a recent decision by OMHA Chief Administrative Law Judge (ALJ) Nancy J. Griswold to defer assignment of appeal requests until the ALJ docket can adequately accommodate such requests, which could add an estimated 28 months to the average adjudication time. Beneficiary-initiated appeals are not subject to the new deferral process.

FDA Final Rule Medical Device Reporting: Electronic Submission Requirements

The FDA has issued a final rule revising its postmarket medical device reporting regulation and making technical corrections. This final rule requires device manufacturers and importers to submit mandatory reports of individual medical device adverse events, also known as medical device reports (MDRs), to the Agency in an electronic format that FDA can process, review and archive. Mandatory electronic reporting will improve the Agency's process for collecting and analyzing postmarket medical device adverse event information. Electronic reporting is also available to user facilities, but this rule permits user facilities to continue to submit written reports to FDA. This final rule also identifies changes to the content of required MDRs to reflect reprocessor information collected on the Form FDA 3500A as required by the Medical Device User Fee and Modernization Act of 2002 (MDUFMA). The final rule is effective Aug. 14, 2015.

Guidance Bulletins Outline Consumer Health Insurance Enrollment Policies

On Feb. 6, CMS issued five guidance bulletins concerning its enrollment and termination policies and its special enrollment period. In the fifth bulletin, titled "Flexibility during the Initial Open Enrollment Period to Change Plans Offered by the Same Issuer at the Same Metal Level," consumers in the federally operated Affordable Care Act (ACA) health insurance marketplaces who have paid their first month's premiums and whose coverage is already effective may change their plans to one with more inclusive provider networks. In order for them to make another plan selection, four criteria must be met, which include: 1) the new plan will maintain the same issuer, 2) the new plan will keep the same actuarial "metal" level and cost-sharing reduction level, 3) the change is to a more inclusive provider network or for other isolated circumstances at the discretion of CMS and 4) the change is being requested within initial open enrollment. Also mentioned, because eligibility isn't being re-determined for enrollees, payment of the advance premium tax credit subsidies won't change. Advance cost-sharing reductions will change, however, because cost-sharing reductions are specific to qualified health plans. Open enrollment for federally operated ACA exchanges ends on March 31.

3. State Activities

Illinois Releases Five-Year Medicaid Restructuring Plan

Illinois Governor Pat Quinn released a five-year Medicaid restructuring plan to secure $5.2 billion from the Federal government. The plan, "The Path to Transformation," expands mental health and addiction treatment services and home and community-based care for the disabled. A spokesman for the Governor said that "by restructuring and streamlining, we can bend the cost curve and spend less in the long run on community care while also provid[ing] better treatment for folks across the board." The proposal must be approved by regulators in order to receive federal funding. Two public hearings on the plan will be held in the next month.

New York Medicaid Waiver Approved by HHS

New York Governor Andrew Cuomo announced Feb. 13 that an agreement has been reached "in principle" with Health and Human Services (HHS) on an $8 billion Medicaid waiver. The waiver is $2 billion less than the state originally sought, but will be necessary to assist "struggling hospitals" that may otherwise have shut down. CMS officials warned that the waiver had not yet been approved, saying the agreement is an important step in that process, which would be finalized in the next few weeks. The state will have to achieve specific benchmarks in order to collect the funding over the five-year period.

Massachusetts Exchange Has New Deadline

On Feb. 13, HHS granted Massachusetts a three-month extension, through June 30, to fix its broken website and get customers enrolled. While CMS has not "formally" granted the extension to the state, officials said CMS will aid the state's efforts to ensure their citizens will be able to enroll in "quality, affordable health coverage." The state had requested a six-month extension from several of the ACA's requirements with which the state has had difficulty complying. Massachusetts, which had already had an instituted exchange-based health care system prior to enactment of the ACA, is often cited as the model on which the ACA was based.

4. Regulations Open for Comment

Children's Hospital Graduate Medical Education (CHGME) Information Collection

The Health Resources and Services Administration (HRSA) has announced plans to submit an Information Collection Request (ICR) to the Office of Management and Budget (OMB) in which data will be collected on the number of full-time equivalent residents in applicant children's hospitals' training programs to determine the amount of direct and indirect medical education payments to be distributed to participating children's hospitals. Assessment of the hospital data ensures that appropriate CMS regulations and Children's Hospitals Graduate Medical Education (CHGME) program guidelines are followed in determining which residents are eligible to be claimed for funding. The audit results impact final payments made by the CHGME Payment Program to all eligible children's hospitals. Indirect medical education payments will also be derived from a formula that requires the reporting of discharges, beds and case mix index information from participating children's hospitals. The CHGME Payment Program was enacted to provide federal support for graduate medical education (GME) to freestanding children's hospitals. This program attempts to provide support for GME comparable to the level of Medicare GME support received by other, non-children's hospitals. Comments are due April 11, 2014.

Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule and the National Instant Criminal Background Check System (NICS)

On Jan. 7, HHS issued a notice of proposed rulemaking to modify the Health Insurance Portability and Accountability Act of 1996 (HIPAA) Privacy Rule to expressly permit certain HIPAA-covered entities to disclose to the National Instant Criminal Background Check System (NICS) the identities of individuals who are subject to a Federal "mental health prohibitor" that disqualifies them from shipping, transporting, possessing or receiving a firearm. The NICS is a national system maintained by the Federal Bureau of Investigation (FBI) to conduct background checks on persons who may be disqualified from receiving firearms based on federally prohibited categories or State law. Among the persons subject to the Federal mental health prohibitor are individuals who have been involuntarily committed to a mental institution; found incompetent to stand trial or not guilty by reason of insanity; or otherwise have been determined by a court, board, commission or other lawful authority to be a danger to themselves or others or to lack the mental capacity to contract or manage their own affairs, as a result of marked subnormal intelligence or mental illness, incompetency, condition or disease. Under this proposal, only covered entities with lawful authority to make adjudication or commitment decisions that make individuals subject to the Federal mental health prohibitor, or that serve as repositories of information for NICS reporting purposes, would be permitted to disclose the information needed for these purposes. Comments are due March 10, 2014.

Contract Year 2015 Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs

On Jan. 6, CMS released a proposed rule that would revise the Medicare Advantage (MA) program (Part C) regulations and prescription drug benefit program (Part D) regulations to implement statutory requirements; strengthen beneficiary protections; exclude plans that perform poorly; improve program efficiencies; and clarify program requirements. Specifically, the proposal includes a requirement establishing U.S. citizenship and lawful presence as eligibility requirements for enrollment in MA and Part D plans. In addition, the proposed rule would modify the administration of payments to agents and brokers who assist Medicare beneficiaries in selecting plans to discourage beneficiaries from enrolling in plans without regard to ensuring plan benefits would meet the beneficiaries' health care needs. Comments are due March 7, 2014.

IRS, HHS, Labor Proposed Rule Defines "Excepted Benefits"

On Dec. 20, the Internal Revenue Service, the Department of Health and Human Services and the Department of Labor proposed rules that would amend the regulations regarding excepted benefits under the Employee Retirement Income Security Act of 1974, the Internal Revenue Code and the Public Health Service Act. Excepted benefits are generally exempt from the health reform requirements that were added to those laws by the Health Insurance Portability and Accountability Act (HIPAA) and the ACA. Specifically, the rules amend the limited excepted benefits category of excepted benefits, which may include limited scope vision or dental benefits, and benefits for long-term care, nursing home care, home health care or community-based care. For an individual to be excepted under this second category, the statute provides that limited benefits must either: (1) be provided under a separate policy, certificate or contract of insurance; or (2) otherwise not be an integral part of a group health plan, whether insured or self-insured. The proposed regulations would eliminate the requirement under the HIPAA regulations that participants pay an additional premium or contribution for limited scope vision or dental benefits to qualify as benefits that are not an integral part of a plan (and therefore as excepted benefits). The Departments invite comments on this approach. Comments are due Feb. 21.

5. Reports


Drug Shortages: Public Health Threat Continues, Despite Efforts to Help Ensure Product Availability

On Feb. 10, GAO released a report entitled "Public Health Threat Continues Despite Efforts to Help Ensure Product Availability," in which the oversight agency identified, as an immediate case of drug shortages, supply disruptions arising from slower drug production by manufacturers focused on resolving problems related to drug safety and quality. In order for the FDA to enhance its oversight of drug shortages, particularly as the agency fine-tunes the manner in which it gathers data on shortages and transitions from its database to a more robust system, GAO recommends that the Commissioner of FDA develop policies and procedures for the use of the existing drug shortages database to ensure staff enter information into the database in a consistent manner and to ensure the accuracy of the information in the database. In addition, GAO recommends that FDA conduct periodic analyses using the existing drug shortages database (and, eventually, the new drug shortages information system) to routinely and systematically assess drug shortage information, and use this information proactively to identify risk factors for potential drug shortages early, thereby potentially helping FDA to recognize trends, clarify causes and resolve problems before drugs go into short supply.


Medicare Improperly Paid Millions of Dollars for Prescription Drugs Provided to Incarcerated Beneficiaries During 2006 Through 2010

In a report released Feb. 10 by the Department of Health and Human Services (HHS) Office of the Inspector General (OIG), between 2006 and 2010 the Centers for Medicare and Medicaid Services (CMS) made almost $12 million in improper payments to Medicare Part D plan sponsors due to deficient internal controls. As it stands, the Medicare Prescription Drug Benefit Manual prohibits Part D coverage for prisoners. Once incarcerated status has been verified, Plan D plan sponsors are supposed to unenroll prisoners from the Part D program. Using a random sampling of 100 incarcerated Medicare beneficiaries, OIG found that CMS accepted 1,298 PDEs submitted by plan sponsors on behalf of 49 inmates, totaling $326,000 in gross drug costs. Citing lack of internal controls to account for its issuance of improper PDEs, OIG found that many plan sponsors had not had in place procedures/policies to handle prescription drug situations for inmates until at least 2010, four years after the Part D program was instituted. OIG recommended that final payment determinations be reopened between 2006 and 2010 to resolve the $326,000 in improper payments cited in the report and reevaluate additional final payment determinations from 2006-2010 before the newly enhanced policies and procedures were implemented by Part D plan sponsors.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions